By Mr Bradley Roberts, Perron Institute & UWA, and Professor Sean Hood, Perron Institute, UWA and SCGH
Researchers at the Perron Institute for Neurological and Translational Science have recently launched the GENE-YD study, an innovative trial exploring the benefits of pharmacogenetic testing to optimise antidepressant pharmacotherapy in young Western Australians.
This pilot randomised controlled trial aims to explore the feasibility for a larger trial in WA to improve treatment outcomes through personalising patients’ antidepressant prescriptions, helping young people achieve symptom relief faster with fewer medication-related side effects.
Major Depressive Disorder (MDD) is among the leading causes...
Researchers at the Perron Institute for Neurological and Translational Science have recently launched the GENE-YD study, an innovative trial exploring the benefits of pharmacogenetic testing to optimise antidepressant pharmacotherapy in young Western Australians.
This pilot randomised controlled trial aims to explore the feasibility for a larger trial in WA to improve treatment outcomes through personalising patients’ antidepressant prescriptions, helping young people achieve symptom relief faster with fewer medication-related side effects.
Major Depressive Disorder (MDD) is among the leading causes...
This content is restricted to site members. If you are an existing user, please log in. New users may register below.